Team:BGU Israel/test/Collaborations

<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

Team:BGU Israel



Collaboration


We have collaborated with a couple of iGEM teams this year:


  • Scientific collaborations -Stockholm
  • Written articles for the Amoy newsletter
  • Collaboration on human practice survey
  • Attended "Mini jamboree" conference hosted by the "Technion"
Introduction

Stockholm team is working on cancer diagnosis by engineering of a bacterial sensor which could detect trace amounts of cancer biomarkers.


Abstract:

Synthetic biology offers many potential cost-effective healthcare technologies. One of those could be new ways to diagnose and treat disease at an early stage. Current techniques for biomarker detection (e.g. ELISA, RIA) are time consuming, expensive and require specialised equipment.


We intend to design a microbiological system for the detection of low quantities of biomarkers. This assay aims to be easier and more cost efficient than existing techniques and possible to perform in modestly equipped settings. Initially, we will focus on the expression of a receptor for the desired biomarker. Depending on the nature of the biomarker, the receptor will be either be native or designed.


Upon biomarker detection, signal amplification will be triggered by our receptor system to activate a read out/detection system (e.g. Luciferase, GFP) inside the microorganism to artificially amplify the extracellular signal. In the next stage, the team will go on to design a read-out system to measure the concentration of biomarkers in body samples. Finally we want to investigate if we can make this system transferable to other biomarkers, changing only the receptor part of the system.


The system would be cheap, fast and possible to distribute without advanced equipment. Our motivation is to improve patient prognosis and quality of life and to improve efficiency and reduce costs within the healthcare system.

link to their wiki

Our assistance to the team is to express an GPI-anchored Affibody [biobrick number??+link] on the plasma membrane of human cancer cells, which can then be specifically targeted by a compatible drug or toxin (Fig. 1).



Fig. 1. Possible applications of Affibody expression in cancer cells.

Results


1. Cloning

We cloned the Affibody [biobrick number??+link] into our AAV vector for expression under CMV promoter (Fig. 2).

Retrieved from "https://2015.igem.org/Team:BGU_Israel/Team"